

Kynmobi (apomorphine)
Effective 11/01/2020

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input checked="" type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		
Specialty Limitations	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Apomorphine is a non-ergoline dopamine agonist. Kynmobi is a sublingual film indicated for acute, intermittent treatment of “off” episodes in patients with Parkinson’s disease.

Coverage Guidelines

Authorization may be granted for members new to the plan who are currently receiving treatment with Kynmobi excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

OR

Authorization may be granted for members when all the following criteria are met, and documentation is provided:

1. The member has a diagnosis of acute, intermittent "off" episodes in patients with Parkinson disease.
2. The member is ≥ 18 years old
3. Provider specialty is neurology or medication is being prescribed in consultation with a neurologist

Continuation of Therapy

Reauthorization requires physician documentation of improvement of member’s condition.

Limitations

1. Initial approvals and reauthorizations will be approved for 12 months.
2. The following quantity limits apply:

Kynmobi	150 films per 30 days
---------	-----------------------

References

1. Kynmobi (apomorphine) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals; May 2020.
2. Hauser RA, Olanow CW, Dzyngel B, et al. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease. *Mov Disord* 2016; 31:1366
3. Olanow CW, Factor SA, Espay AJ, et al. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. *Lancet Neurol* 2020; 19:135

Review History

09/16/2020 – Reviewed and Created Sept P&T Mtg. Effective 11/01/20.

09/22/2021 – Reviewed P&T; reworded overview; references updated; no clinical updates

11/16/2022 – Reviewed for Nov P&T. Separated out MH vs Comm/Exch. No clinical changes.

